In a nutshell This study aimed to compare the safety and effectiveness of duvelisib (Copiktra) and ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia. This study concluded that duvelisib was an effective treatment option for these patients. Some background Chronic lymphocytic leukemia (CLL) is the most common...
Read MoreCurrent disease status-Recurrent leukemia Posts on Medivizor
Sequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine
In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...
Read MoreEvaluating duvelisib for the treatment of CLL
In a nutshell This study evaluated the effectiveness and safety of duvelisib in patients with chronic lymphocytic leukemia (CLL). This study concluded that duvelisib may be an effective new therapy with manageable side effects. Some background CLL is the most common type of leukemia in adults in the U.S. Although therapy options have increased, many...
Read MoreCan Gemtuzumab Ozagamicin help children with unresponsive Acute Myeloid Leukemia?
In a nutshell This study observed the safety and effectiveness of the drug Gemtuzumab Ozagamicin (Mylotarg) when given to children with acute myeloid leukemia unresponsive to treatment. The authors found the treatment to be effective in children who became unresponsive to bone marrow transplant therapy. Some background Acute Myeloid...
Read MoreEvaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia
In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...
Read MoreThe safety and effectiveness of nilotinib in the treatment of unresponsive CML
In a nutshell This study examined the safety and effectiveness of using nilotinib (Tasigna) in patients with chronic myeloid leukemia (CML) unresponsive to other treatment. The study concluded that nilotinib is safe and effective in the treatment of CML unresponsive to imatinib (Gleevec). Some background Chronic myeloid leukemia is a cancer of the...
Read MoreOutcomes and management of CLL treated with venetoclax
In a nutshell This study examined the safety and effectiveness of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). Researchers found that venetoclax was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a type of cancer of the bone marrow that can lead to an abnormal immune system. Over...
Read MoreNilotinib versus imatinib in the treatment of CML
In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...
Read MoreWhat major factors affect disease progression and outcome in adults with acute myeloid leukemia?
In a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...
Read MoreThe safety of blinatumomab in the treatment of ALL
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) compared with standard chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). The study found that blinatumomab was a safe and effective treatment option compared to chemotherapy in patients with ALL. Some background Acute lymphoblastic leukemia is...
Read MoreIs plerixafor a safe addition to chemotherapy treatment for AML?
In a nutshell This study looked at the safety and effectiveness of adding plerixafor (Mozibil) to FLAG-Ida (fludarabine [Fludara], idarubicin [Idamycin], cytarabine [Cytosar-U] and G-CSF) in the treatment of patients with relapsed acute myeloid leukemia. The study found that adding plerixafor to FLAG-Ida treatment (together called PLERIFLAG) was a safe...
Read MorePonatinib as a second-line treatment for chronic-phase chronic myeloid leukemia
In a nutshell This study aimed to investigate if ponatinib is a suitable second-line treatment option for patients with chronic-phase chronic myeloid leukemia. This study concluded that ponatinib is a suitable option for these patients. Some background Ponatinib (Iclusig) is a tyrosine kinase inhibitor (TKI). TKIs work by blocking proteins...
Read More